Among the many endocrine abnormalities found in chronic renal failure, thyroid abnormalities were some of the earliest to be studied. The explanation for these alterations in thyroid anatomy and physiology has however so far remained elusive. Conflicting data abound in literature, especially regarding the presence of goiter.
Estimates of goiter in dialysis patients have ranged from 0 to 60% (1-8) (Tab. I). This variability may be due in part to the inexactitude of the physical examination and to observer bias. The general consensus, however, is that the thyroid gland is often enlarged. Thus in a recent prospective study of 306 dialysis patients, 43% were found to have a goiter, defined as a thyroid visible on swallowing or readily palpable. In this study the incidence of goiter was directly related to the number of years on dialysis. In another study (8) the thyroid gland volume estimated by ultrasound was greatly increased in dialysis patients compared to controls, despite not being evident on clinical examination. The increased prevalence of goiter in end stage renal disease (ESRD), irrespective of geographic area, implies that some factor in uremia acts as a goitrogen.
Presumed goitrogenic factors include altered iodide metabolism and parathyroid abnormalities (9) . In the United States the average iodine intake greatly exceeds the minimum daily requirement because of supplementation and contamination of food and drugs. Thus goiter due to iodine deficiency is no longer seen. Iodide is removed from the plasma chiefly by the thyroid and kidney, the latter being largely a function of glomerular filtration rate. Despite clearance by hemodialysis (iodide dialysance = urea dialysance), plasma inorganic iodide levels in chronic renal failure remain high (10) . The iodine uptake by the thyroid is thought to be increased in ESRD, but the biosynthesis of active hormones is suppressed (10) .
Iodine itself, given in large doses, can block the organic binding and coupling reactions necessary for thyroid hormone synthesis (11) . This action, known as the Wolff-Chaikoff effect, is usually transient; but in some normal people the prolonged administration of iodide causes persistent hormone synthesis inhibition and the development of goiter with or without hypothyroidism (11) . Thyroid stimulating hormone (TSH) influences the sensitivity of the thyroid to this Wolff-Chaikoff effect (11) . The effects of TSH are more variable but in a gland chronically stimulated by TSH a smaller dose of iodide is required to induce the Wolff-Chaikoff effect. Most patients with ESRD have normal or high normal levels of TSH, although consistenly high levels have been reported (12, 13) .
The effect of excess iodide on the thyroid varies between species. In the mouse large doses of iodine cause thyroid enlargment (14) . The uremic rat exhibits a rise in TSH when supplemented with iodine, and there is a direct correlation between serum iodide levels and thyroid gland weight (15) . In humans, iodine deficiency is a well known cause of goiter, but it is unclear whether chronic iodine excess is goitrogenic. Although the exact incidence of iodide-excess goiter is unknown, it is thought to be rare. It is noted that patients who develop iodide-excess goiter have received large quantities of iodine for a long time, months to years. A fascinating type of iodideinduced goiter is found on the Japanese island of Hokkaido (11) . This endemic "coastal goiter" occurs primarily in fishermen and their familes who eat large amounts of iodine rich seaweed. Certain weak goitrogens, such as sulfonamides and antipyrine, are much more potent when given with excess iodine (16) .
Most patients with chronic renal failure have abnormal serum inorganic iodine and protein bound iodine (PSI) levels. Elevated iodine levels are found in 84-92% of dialysis patients (17) . Furthermore, a significant direct correlation between TSH levels and the serum levels of inorganic iodine has been observed (17) . It is thus possible that the chronically elevated iodine levels associated with a normal to high TSH level may produce goiter, perhaps through a chronic Wolff-Chaikoff effect.
Parathyroid hormone (PTH), an undoubted uremic toxin, has been implicated in many of the abnormalities of the uremic state. Evidence exists, especially in surgical literature, of a correlation between hyperparathyroidism and thyroid disease (18, 19) . Studies in primary hyperparathyroidism have shown an incidence of thyroid nodules or goiter in over 20% of patients at surgery and in over 60% at autopsy (19) . An increase in malignant and non-malignant thyroid lesions occurs in primary hyperparathyroidism (20, 21) . The parallel increase in secondary hyperparathyroidism and goiter incidence is consistent with the proliferative properties of PTH (7) , lending credence to a role for PTH in the genesis of uremic goiter. What has not been determined is whether, like other weak goitrogens, the effects of PTH are magnified by chronic iodine excess.
From available evidence the incidence of goiter appears to be increased in dialysis patients. Its etiology remains unclear and does not seem to result in either hypo or hyperthryoidism. Chronic iodine excess is likely to be a predisposing factor for various minor goitrogens. The reports of thyroid malignancy in dialysis patients (20, 21, 22) deserve greater scrutiny, and suggest that uremic goiter cannot be said at this time to be definitely benign. 
